ウイルス療法で抗生物質耐性菌を克服(UC San Diego Researchers Expand Virus-Based Treatment Options for Antibiotic-Resistant Infections)

ad

2025-11-19 カリフォルニア大学サンディエゴ校 (UCSD)

抗生物質耐性菌の増加は世界的な公衆衛生課題であり、多剤耐性菌に対する従来の抗生物質の有効性が低下している。UC San Diego の研究者らは、バクテリオファージ(細菌を標的に感染・殺菌するウイルス)を用いた治療法を進化させる新しい手法を開発した。具体的には、ファージと標的となる耐性菌(例えば Klebsiella pneumoniae など)を試験管内で共培養し、ファージが細菌に対してより広範な宿主範囲を持つよう“訓練”し、耐性菌株全体に対する殺菌効果と持続的抑制効果を向上させた。研究成果では、従来のファージ株よりもさまざまな薬剤耐性株を殺す能力が向上し、細菌の増殖再開を長時間抑制できたという。これは、抗生物質が効かない場合の代替あるいは併用治療として、ファージ治療の実用化を後押しするものである。研究チームは今後、臨床前研究および実用製造への展開を進める方針を示しており、抗菌耐性への新たな「ウイルス戦略」が医療現場における重要な選択肢になる可能性が高い。

ウイルス療法で抗生物質耐性菌を克服(UC San Diego Researchers Expand Virus-Based Treatment Options for Antibiotic-Resistant Infections)
Phages attack and kill harmful bacteria and could be used to address the growing problem of deadly antibiotic-resistant infections. Photo credit: iStock

<関連情報>

実験的ファージ進化により抗生物質耐性肺炎桿菌分離株に対する宿主域が拡大 Experimental phage evolution results in expanded host ranges against antibiotic resistant Klebsiella pneumoniae isolates

Pooja Ghatbale,Alisha Blanc,Andrew Sue,Jesse Leonard,Monica Bates,Andrew G. Garcia,Joshua Hensley,Danielle Devequi Gomes Nunes,Nicole Hitchcock,Job Shiach,Roberto Bardaró,Govind Sah,Chandrabali Ghose,Katrine L. Whiteson,Robert T. Schooley,Richard Allen White III,Ana G. Cobián Güemes,Justin R. Meyer & David T. Pride
Nature Communications  Published:19 November 2025
DOI:https://doi.org/10.1038/s41467-025-66062-7

Fig. 1

Abstract

Resistance to antibiotics is approaching crisis levels for organisms such as the ESKAPEE pathogens (includes Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp., and Escherichia coli) that often are acquired in hospitals. These organisms sometimes have acquired plasmids that confer resistance to most if not all beta-lactam antibiotics. We have been developing alternative means for dealing with antibiotic resistant microbes that cause infections in humans by developing viruses (bacteriophages) that attack and kill them. One of these pathogens, K. pneumoniae, has one of the highest propensities for antimicrobial resistance. We identified many phages that have lytic capacity against limited numbers of clinical isolates, and through experimental evolution over the course of 30 days, were able to vastly expand the host ranges of these phages to kill a broader range of clinical K. pneumoniae isolates including MDR (multi-drug resistant) and XDR (extensively-drug resistant) isolates. Most interestingly, they were capable of inhibiting growth of clinical isolates both on solid and in liquid medium over extended periods. That we were able to extend the host ranges of multiple naïve antibiotic resistant K. pneumoniae through experimental phage evolution suggests that such a technique may be applicable to other antibiotic-resistant organisms to help stem the tide of antibiotic resistance and offer further options for medical treatments.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました